Last reviewed · How we verify
GEMOX
Gemcitabine and oxaliplatin combination chemotherapy
Gemcitabine and oxaliplatin combination chemotherapy Used for Colorectal cancer.
At a glance
| Generic name | GEMOX |
|---|---|
| Also known as | Gemcitabine plus oxaliplatin, Gemcitabine, Oxaliplatin |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gemcitabine and oxaliplatin combination chemotherapy is a chemotherapy regimen that uses the drugs gemcitabine and oxaliplatin to kill cancer cells. Gemcitabine is a nucleoside analog that interferes with DNA synthesis, while oxaliplatin is a platinum-based drug that cross-links DNA, causing DNA damage and apoptosis in cancer cells.
Approved indications
- Colorectal cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Diarrhea
Key clinical trials
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (PHASE2)
- Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PHASE3)
- Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (PHASE3)
- Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma (PHASE2)
- Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
- Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer (PHASE1, PHASE2)
- A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GEMOX CI brief — competitive landscape report
- GEMOX updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI